JP2017529059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529059A5 JP2017529059A5 JP2016576027A JP2016576027A JP2017529059A5 JP 2017529059 A5 JP2017529059 A5 JP 2017529059A5 JP 2016576027 A JP2016576027 A JP 2016576027A JP 2016576027 A JP2016576027 A JP 2016576027A JP 2017529059 A5 JP2017529059 A5 JP 2017529059A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- modified
- dimer
- modified gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 239000000539 dimer Substances 0.000 claims description 26
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 21
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108010071390 Serum Albumin Proteins 0.000 claims description 9
- 102000007562 Serum Albumin Human genes 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 7
- 102220005382 rs33914470 Human genes 0.000 claims description 6
- 102220143003 rs753997345 Human genes 0.000 claims description 6
- 102220025225 rs199476363 Human genes 0.000 claims description 5
- 102220123860 rs61760902 Human genes 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102220353134 c.68G>A Human genes 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102200078418 rs1805085 Human genes 0.000 claims description 3
- 102220503690 GTP-binding protein REM 1_T94N_mutation Human genes 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 102200150805 rs1057519492 Human genes 0.000 claims description 2
- 102220230165 rs1064793071 Human genes 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102200090880 rs28933100 Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 102220058798 rs786202903 Human genes 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102200075235 rs118204106 Human genes 0.000 description 1
- 102220248744 rs145985140 Human genes 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031063P | 2014-07-30 | 2014-07-30 | |
| US62/031,063 | 2014-07-30 | ||
| US201562195908P | 2015-07-23 | 2015-07-23 | |
| US62/195,908 | 2015-07-23 | ||
| PCT/US2015/042510 WO2016018931A1 (en) | 2014-07-30 | 2015-07-28 | Compositions and methods of use for treating metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529059A JP2017529059A (ja) | 2017-10-05 |
| JP2017529059A5 true JP2017529059A5 (enExample) | 2018-09-06 |
| JP6704358B2 JP6704358B2 (ja) | 2020-06-03 |
Family
ID=55179329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016576027A Active JP6704358B2 (ja) | 2014-07-30 | 2015-07-28 | 代謝障害を治療するための組成物および使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9834586B2 (enExample) |
| EP (1) | EP3174894B1 (enExample) |
| JP (1) | JP6704358B2 (enExample) |
| KR (1) | KR20170065026A (enExample) |
| CN (1) | CN106573966B (enExample) |
| AP (1) | AP2016009663A0 (enExample) |
| AU (1) | AU2015296640B2 (enExample) |
| CA (1) | CA2953827A1 (enExample) |
| CL (1) | CL2017000201A1 (enExample) |
| CO (1) | CO2017000614A2 (enExample) |
| CR (1) | CR20170027A (enExample) |
| DO (1) | DOP2017000025A (enExample) |
| EA (1) | EA035581B1 (enExample) |
| EC (1) | ECSP17005276A (enExample) |
| ES (1) | ES2883158T3 (enExample) |
| IL (1) | IL249793B (enExample) |
| MD (1) | MD20170020A2 (enExample) |
| MX (1) | MX370115B (enExample) |
| MY (1) | MY192917A (enExample) |
| PE (1) | PE20170771A1 (enExample) |
| PH (1) | PH12017500153B1 (enExample) |
| SG (2) | SG10201802098UA (enExample) |
| SV (1) | SV2017005367A (enExample) |
| TN (1) | TN2016000578A1 (enExample) |
| TW (1) | TWI710570B (enExample) |
| UA (1) | UA123432C2 (enExample) |
| WO (1) | WO2016018931A1 (enExample) |
| ZA (1) | ZA201700311B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9714276B2 (en) | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| WO2015117024A1 (en) | 2014-01-31 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Novel therapeutics for the treatment of glaucoma |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| MD20170035A2 (ro) * | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
| CN117986363A (zh) | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| MA45113A (fr) | 2016-05-24 | 2019-04-10 | Novo Nordisk As | Composés mic-1 et leur utilisation |
| WO2018068047A1 (en) * | 2016-10-07 | 2018-04-12 | Beth Israel Deaconess Medical Center, Inc. | Compositions comprising relaxin and methods of use thereof |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| WO2018193033A1 (en) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
| JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー／エス | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ |
| US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN111954537A (zh) | 2018-04-09 | 2020-11-17 | 美国安进公司 | 生长分化因子15融合蛋白 |
| JP2021533743A (ja) | 2018-08-10 | 2021-12-09 | ノバルティス アーゲー | Ｇｆｒａｌ細胞外ドメイン及び使用方法 |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| KR20210081389A (ko) | 2018-10-22 | 2021-07-01 | 얀센 파마슈티카 엔.브이. | 글루카곤 유사 펩티드 1(glp1)-성장 분화 인자 15(gdf15) 융합 단백질 및 이의 용도 |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| BR112022010227A2 (pt) * | 2019-11-26 | 2022-09-13 | Yuhan Corp | Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma |
| AU2020400805B2 (en) * | 2019-12-11 | 2024-03-28 | Lg Chem, Ltd. | Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation |
| AU2020403144A1 (en) | 2019-12-12 | 2022-07-14 | Mayo Foundation For Medical Education And Research | Controlled-delivery cromakalim prodrugs |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ |
| JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE69637844D1 (de) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
| US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| NZ334592A (en) | 1996-09-11 | 2000-10-27 | Ortho Mcneil Pharm Inc | Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer |
| WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| WO2000005259A1 (en) | 1998-07-23 | 2000-02-03 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| WO2000070051A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| DK1266006T3 (da) * | 2000-03-22 | 2006-01-16 | Octagene Gmbh | Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| ES2300325T3 (es) | 2000-04-20 | 2008-06-16 | St Vincent's Hospital Sydney Limited | Ensayo diagnostico que implica la citoquina 1 inhibitoria de macrofagos (mc1). |
| US7141661B2 (en) | 2000-09-08 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| EP1354042A2 (en) | 2000-12-29 | 2003-10-22 | Curagen Corporation | Proteins and nucleic acids encoding same |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| EP1395605B8 (en) | 2001-03-09 | 2014-12-17 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| JP4516719B2 (ja) | 2001-05-11 | 2010-08-04 | アムジエン・インコーポレーテツド | Ｔａｌｌ−１と結合するペプチド及び関連分子 |
| GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
| ES2425738T3 (es) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| US20040253207A1 (en) | 2002-11-08 | 2004-12-16 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| PT2441466E (pt) | 2004-04-13 | 2014-09-09 | St Vincents Hosp Sydney | Agente de inibição de mic-1 |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| CN101724071A (zh) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
| HRP20160990T1 (hr) | 2006-03-24 | 2016-10-07 | Biogen Hemophilia Inc. | Pc5 kao enzim obrade faktor ix propeptida |
| US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
| BRPI0712496A2 (pt) | 2006-06-02 | 2012-09-25 | Wyeth Corp | peptìdeo isolado, composição compreendendo o referido peptìdeo, ácido nucléico isolado e métodos de purificar uma proteìna na superfamìlia do fator beta de transformação do crescimento (tgf-?) e de estabilizar uma solução contendo uma proteìna na superfamìlia tgf-b. |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| CA2659225A1 (en) | 2006-07-26 | 2008-01-31 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
| EP2047275B1 (en) | 2006-08-04 | 2011-06-01 | Medizinische Hochschule Hannover | Methods for assessing the risk of cardiac interventions based on gdf-15 |
| WO2008133536A2 (en) | 2007-04-25 | 2008-11-06 | Akademia Medyczna Im. Piastow Slaskich We Wroclawiu | New stem cell lines, their application and culture methods |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| AU2008281913B2 (en) | 2007-07-31 | 2013-11-07 | Affibody Ab | New albumin binding compositions, methods and uses |
| CA2694863A1 (en) | 2007-08-16 | 2009-02-19 | Garvan Institute Of Medical Research | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| US20100266707A1 (en) | 2007-10-09 | 2010-10-21 | Samuel Norbert Breit | Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| CA2701945A1 (en) | 2007-10-22 | 2009-04-30 | Samuel Norbert Breit | Methods of prognosis of overall survival using mic-1 |
| CA2704207A1 (en) * | 2007-10-29 | 2009-05-07 | Virginia Tech Intellectual Properties, Inc. | Porcine dc-sign, icam-3 and lsectin and uses thereof |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2009089396A2 (en) | 2008-01-08 | 2009-07-16 | Neose Technologies, Inc. | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| JP2011509403A (ja) | 2008-01-08 | 2011-03-24 | エフ．ホフマン−ラ ロシュ アーゲー | Ｇｄｆ−１５に基づいて救急室を受診する患者のリスクを評価するための手段及び方法 |
| WO2009121804A1 (en) * | 2008-03-31 | 2009-10-08 | Glaxo Group Limited | Drug fusions and conjugates |
| WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| EP2318844A1 (en) | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| CN102203619B (zh) | 2008-10-31 | 2015-12-16 | 圣文森特医院悉尼有限公司 | 慢性肾病中的预测方法 |
| CA2742267C (en) | 2008-10-31 | 2019-06-04 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| CA2752157A1 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease |
| GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
| KR101558642B1 (ko) | 2009-02-24 | 2015-10-12 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드 |
| SMT202400036T1 (it) | 2009-05-05 | 2024-03-13 | Amgen Inc | Mutanti fgf21 e loro utilizzi |
| AU2010270844A1 (en) | 2009-07-08 | 2011-12-22 | Amgen Inc. | Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering |
| WO2011008956A2 (en) | 2009-07-15 | 2011-01-20 | Zirus, Inc. | Mammalian genes involved in infection |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| CN105274170A (zh) | 2009-11-05 | 2016-01-27 | 弗·哈夫曼-拉罗切有限公司 | 分泌异源多肽的方法和组合物 |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
| US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
| EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
| ES2534921T3 (es) | 2010-08-26 | 2015-04-30 | F. Hoffmann-La Roche Ag | Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| EP2670847B1 (en) * | 2011-02-03 | 2016-10-05 | XOMA Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| US10752664B2 (en) | 2011-04-08 | 2020-08-25 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
| EP2697257B1 (en) | 2011-04-13 | 2016-10-19 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| BR112013030472A2 (pt) | 2011-06-30 | 2019-09-24 | Genentech Inc | formulação farmacêutica, artigo de fabricação e método |
| US9890218B2 (en) | 2011-06-30 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| US9714276B2 (en) | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| PE20150645A1 (es) | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
| MX370720B (es) | 2012-12-21 | 2019-12-20 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15. |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2970422B1 (en) | 2013-03-15 | 2018-04-18 | F.Hoffmann-La Roche Ag | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| CN203123206U (zh) * | 2013-04-01 | 2013-08-14 | 宋艳丽 | 一种简易式一次性防污染无菌注射器 |
| MX2016001165A (es) | 2013-07-31 | 2016-06-29 | Amgen Inc | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. |
| TN2016000035A1 (en) | 2013-07-31 | 2017-07-05 | Amgen Inc | Growth differentiation factor 15 (gdf-15) constructs |
| UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
| WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
-
2015
- 2015-07-28 UA UAA201700670A patent/UA123432C2/uk unknown
- 2015-07-28 TW TW104124401A patent/TWI710570B/zh active
- 2015-07-28 PE PE2017000103A patent/PE20170771A1/es unknown
- 2015-07-28 ES ES15827485T patent/ES2883158T3/es active Active
- 2015-07-28 SG SG10201802098UA patent/SG10201802098UA/en unknown
- 2015-07-28 JP JP2016576027A patent/JP6704358B2/ja active Active
- 2015-07-28 TN TN2016000578A patent/TN2016000578A1/en unknown
- 2015-07-28 CA CA2953827A patent/CA2953827A1/en active Pending
- 2015-07-28 US US14/811,578 patent/US9834586B2/en not_active Expired - Fee Related
- 2015-07-28 AP AP2016009663A patent/AP2016009663A0/en unknown
- 2015-07-28 MX MX2017000964A patent/MX370115B/es active IP Right Grant
- 2015-07-28 CN CN201580041716.9A patent/CN106573966B/zh active Active
- 2015-07-28 AU AU2015296640A patent/AU2015296640B2/en not_active Ceased
- 2015-07-28 WO PCT/US2015/042510 patent/WO2016018931A1/en not_active Ceased
- 2015-07-28 SG SG11201700378PA patent/SG11201700378PA/en unknown
- 2015-07-28 EA EA201692477A patent/EA035581B1/ru unknown
- 2015-07-28 KR KR1020177002592A patent/KR20170065026A/ko not_active Withdrawn
- 2015-07-28 MD MDA20170020A patent/MD20170020A2/ro not_active Application Discontinuation
- 2015-07-28 EP EP15827485.2A patent/EP3174894B1/en active Active
- 2015-07-28 MY MYPI2017700310A patent/MY192917A/en unknown
- 2015-07-28 CR CR20170027A patent/CR20170027A/es unknown
-
2016
- 2016-12-27 IL IL249793A patent/IL249793B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00311A patent/ZA201700311B/en unknown
- 2017-01-24 PH PH12017500153A patent/PH12017500153B1/en unknown
- 2017-01-25 EC ECIEPI20175276A patent/ECSP17005276A/es unknown
- 2017-01-25 CO CONC2017/0000614A patent/CO2017000614A2/es unknown
- 2017-01-25 DO DO2017000025A patent/DOP2017000025A/es unknown
- 2017-01-25 SV SV2017005367A patent/SV2017005367A/es unknown
- 2017-01-25 CL CL2017000201A patent/CL2017000201A1/es unknown
- 2017-11-01 US US15/801,198 patent/US20180134761A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,877 patent/US11358995B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529059A5 (enExample) | ||
| US12173060B2 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP2016511752A5 (enExample) | ||
| CN105980400B (zh) | 生长分化因子15(gdf-15)构建体 | |
| CN102781960B (zh) | Hsa相关组合物及使用方法 | |
| CN106573966B (zh) | 用于治疗代谢异常的组合物和方法 | |
| CN102625811B (zh) | Fgf21突变体及其用途 | |
| JP5801807B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| JP2017538395A5 (enExample) | ||
| RU2015136440A (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| KR20020026558A (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| WO2018166468A1 (zh) | IgG样长效免疫融合蛋白及其应用 | |
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| JP2023096044A (ja) | 免疫調節融合タンパク質 | |
| CA3000697A1 (en) | Treatment of bile acid disorders | |
| JP2009510999A (ja) | キメラ治療剤 | |
| CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
| KR20250166188A (ko) | Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법 | |
| CN109400711B (zh) | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| CN113874393A (zh) | 对hbv包膜蛋白具有特异性的结合分子 | |
| CN117186239A (zh) | 融合蛋白及其应用 | |
| JP7681684B2 (ja) | 成長ホルモン融合タンパク質及びその調製方法並びに使用 |